Abstracts tagged "ANCA"

Abstract Number: 2643 • 2019 ACR/ARP Annual Meeting
Comparative Study of Renal Transplantation Due to Rapidly Progressive Glomerulonephritis (RPGN): Study of 42 Patients from a Single Tertiary Centre
Lara Sanchez-Bilbao¹, Marina De Cos-Gomez ², Iñigo Gonzalez-Mazon ³, Belén Atienza-Mateo ¹, Jose Luis Martín-Varillas ¹, Mónica Calderón-Goercke ⁴, DIANA PRIETO- PENA ³, Juan Carlos Ruiz-San Millan ², Miguel A Gonzalez-Gay ¹ and Ricardo Blanco ¹, ¹Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain, ²Nephrology, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ³Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ⁴Hospital Marqués de Valdecilla, Santander, Cantabria, Spain
Background/Purpose: Rapidly Progressive Glomerulonephritis (RPGN) is characterized clinically by a rapid and severe decline in kidney function. Thus, this entity may lead to an end…
Abstract Number: 871 • 2019 ACR/ARP Annual Meeting
ANCA-Associated Vasculitis Management in the United States: Data from the RISE Registry
Zachary Wallace¹, Huifeng Yun ², Jeffrey Curtis ², Shuo Yang ², Lang Chen ², John Stone ³ and Hyon K. Choi ⁴, ¹Massachusetts General Hospital, Boston, ²University of Alabama at Birmingham, Birmingham, AL, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ⁴Massachusetts General Hospital, Boston, MA
Background/Purpose: The management of ANCA-associated vasculitis (AAV) evolved substantially in recent years because of evidence supporting the efficacy of various treatment regimens. As such, treatment…
Abstract Number: 1681 • 2019 ACR/ARP Annual Meeting
The Association of Reduced Low-Density Lipoprotein (LDL) Cholesterol Levels with ANCA-Associated Vasculitis (AAV)
Zachary Wallace¹, Xiaoqing Fu ¹, Yuqing Zhang ², John Stone ³ and Hyon K. Choi ², ¹Massachusetts General Hospital, Boston, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: ANCA-associated vasculitis (AAV) is a small vessel vasculitis associated with an intense inflammatory state. AAV patients are at a 2-fold higher risk of cardiovascular…
Abstract Number: 2786 • 2019 ACR/ARP Annual Meeting
Renal Histopathological Classifications Predict the Renal Outcomes of Plasma Exchange-Treated ANCA-Associated Vasculitides with Renal Failure
Dorian Nezam ¹, Pauline Morel ¹, Stanislas Faguer ², Alexandre Karras ³, Julien Aniort ⁴, Dimitri Titeca-Beauport ⁵, Justine Solignac ⁶, Didier Ducloux ⁷, Rafik Mesbah ⁸, Pierre-Louis Carron ⁹, Cédric Rafat ¹⁰, Pierre Gobert ¹¹, Vincent Audard ¹², Séverine Beaudreuil ¹³, François Maurier ¹⁴, Nihal Martis ¹⁵, Aurélien Tiple ⁴, Stéphane Bally ¹⁶, Aurélie Hummel ¹⁷, Claire de Moreuil ¹⁸, Tiphaine Goulenok ¹⁷, Dominique Nochy ¹⁹, Noémie Jourde-Chiche ²⁰, Alexis Régent ²¹, Loic Guillevin ²¹ and Benjamin Terrier²¹, ¹Cochin Hospital, Paris, France, ²CHU Toulouse, Toulouse, France, ³Paris HEGP, Paris, France, ⁴CHU, Clermont-Ferrand, France, ⁵CHU, Amiens, France, ⁶CHU, Marseille, France, ⁷CHU, Besancon, France, ⁸CH, Boulogne sur Mer, France, ⁹Grenoble, Grenoble, France, ¹⁰Tenon Hospital, Paris, France, ¹¹Clinique Rhone Durance, Avignon, France, ¹²Henri Mondor Hospital, Créteil, France, ¹³Bicetre Hospital, Le Kremlin Bicetre, France, ¹⁴Service de Médecine Interne, Hôpital Belle Isle, Metz, Metz, France, ¹⁵CHU, Nice, France, ¹⁶CH, Chambery, France, ¹⁷APHP, Paris, France, ¹⁸CHU Brest, Brest, France, ¹⁹HEGP Hospital, Paris, France, ²⁰APHM, Marseille, Marseille, France, ²¹National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France
Background/Purpose: ANCA-associated vasculitides (AAVs) are the most frequent cause of rapidly progressive glomerulonephritis (RPGN), for which the major prognostic issue is the risk of developing…
Abstract Number: 874 • 2019 ACR/ARP Annual Meeting
Comparative Analysis Between ANCA-associated Interstitial Lung Disease and Interstitial Pneumonitis with Autoimmune Features
Iazsmin Ventura¹, Anisha Dua ², Ayodeji Adegunsoye ³, Mary Strek ³, James Curran ¹, Alexandra Weiss ¹ and Jonathan Chung ¹, ¹University of Chicago, Chicago, ²Northwestern University Feinberg School of Medicine, Chicago, IL, ³University of Chicago, Department of Pulmonary and Critical Care, Chicago
Background/Purpose: Anti-neutrophil cytoplasmic antibodies (ANCA) have been identified in patients who have pneumonia without a diagnosis of ANCA-associated vasculitis (AAV). These patients are presently categorized…
Abstract Number: 1682 • 2019 ACR/ARP Annual Meeting
Inpatient Epidemiology of Granulomatosis with Polyangiitis in the United States
Patompong Ungprasert¹, Matthew Koster ², Wisit Cheungpasitporn ³, Karn Wijarnpreecha ⁴, Charat Thongprayoon ² and Paul Kroner ⁵, ¹Cleveland Clinic, Cleveland, OH, Bangkok, Thailand, ²Mayo Clinic Rochester, Rochester, MN, ³University of Mississippi Medical Center, Jackson, MS, ⁴Mayo Clinic Florida, Jacksonville, FL, ⁵Mayo Clinic Florida, Jacksonville
Background/Purpose: Granulomatosis with polyangiitis (GPA, formerly known and Wegener’s granulomatosis) is a major subtype of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis characterized by granulomatous inflammation of…
Abstract Number: 2787 • 2019 ACR/ARP Annual Meeting
Predictors of Renal Involvement in ANCA-Associated Vasculitis
Andreas Kronbichler ¹, Jae Il Shin ², Keum Hwa Lee ², Daiki Nakagomi ³, Luis Quintana ⁴, Martin Busch ⁵, Anthea Craven ⁶, Raashid Luqmani ⁶, Peter Merkel⁷, Gert Mayer ¹, David Jayne ⁸ and Richard Watts ⁹, ¹Medical University Innsbruck, Innsbruck, Austria, ²Yonsei University College of Medicine, Seoul, Republic of Korea, ³University of Yamanashi, Yamanashi, Japan, ⁴University of Barcelona, Barcelona, Spain, ⁵University of Jena, Jena, Germany, ⁶University of Oxford, Oxford, United Kingdom, ⁷University of Pennsylvania, Philadelphia, PA, ⁸Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, UK, Cambridge, United Kingdom, ⁹University of East Anglia, Norwich, United Kingdom
Background/Purpose: Renal involvement in the context of anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV) is associated with significant morbidity and higher mortality rates. This study examined…
Abstract Number: 966 • 2019 ACR/ARP Annual Meeting
Minimal Residual Autoimmunity After Rituximab in ANCA-associated Vasculitis Patients
Laura van Dam¹, Jelle Oskam ², Sylvia Kamerling ², Eline Arends ², Edwin Bredewold ², Magda Berkowska ², Jacques van Dongen ², Ton Rabelink ², Cees van Kooten ² and Onno Teng ², ¹LUMC, Leiden, Zuid-Holland, Netherlands, ²LUMC, Leiden, Netherlands
Background/Purpose: Background: B-cell depletion with rituximab (RTX) is an effective treatment for ANCA-associated vasculitis (AAV) patients. Repeated RTX upon B-cell repopulation or return of ANCAs…
Abstract Number: 1704 • 2019 ACR/ARP Annual Meeting
Efficacy of Leflunomide for Treatment of Vasculitis
NOURA MUSTAPHA ¹, Lillian Barra ², Simon Carette ³, David Cuthbertson ⁴, Nader A. Khalidi ⁵, Curry L. Koening ⁶, Carol Langford ⁷, Carol McAlear ⁸, Nataliya Milman ⁹, Larry Moreland ¹⁰, Paul Monach ¹¹, Philip Seo ¹², Ulrich Specks ¹³, Antoine Sreih ¹⁴, Steven Ytterberg ¹³, Peter Merkel ¹⁴, Christian Pagnoux¹⁵, CanVasc Canadian Vasculitis Research Network ¹⁶ and VCRC Vasculitis Clinical Research Consortium ⁸, ¹Hopital Notre Dame, Montreal, QC, Canada, ²St Joseph's health care, London, Canada, ³Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, Canada, ⁴University of South Florida, Tampa, FL, ⁵McMaster University, Hamilton, ON, Canada, ⁶University of Utah Hospital, Salt Lake City, UT, ⁷Cleveland Clinic, Cleveland, OH, ⁸University of Pennsylvania, Division of Rheumatology, Philadelphia, ⁹Arthritis Centre at the Ottawa Hospital, Riverside Campus, Ottawa, Canada, ¹⁰University of Pittsburgh, PITTSBURGH, PA, ¹¹Brigham and Women's Hospital, Boston, MA, ¹²Johns Hopkins Medicine, Baltimore, MD, ¹³Mayo Clinic College of Medicine, Rochester, MN, ¹⁴University of Pennsylvania, Philadelphia, PA, ¹⁵Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, ¹⁶Mount Sinai Hospital, Vasculitis clinic, toronto, ON, Canada
Background/Purpose: Only a few small case series, case reports, and one small clinical trial suggested some benefit of leflunomide (LEF) in ANCA-associated vasculitis and other…
Abstract Number: 970 • 2019 ACR/ARP Annual Meeting
New-onset ANCA-associated Vasculitis Is Associated with Significant Phenotypic B Cell Dysfunction
Emilie Chan¹, Susan Hartzell ², Lisa Anderson ², Chiara Cantarelli ², Chiara Guglielmo ², Ioannis Tassiulas ³, Sofia Andrighetto ², Andrea Angeletti ⁴, Joaquin Manrique Escola ⁵ and Paolo Cravedi ², ¹Mount Sinai Hospital, New York, NY, ²Mount Sinai Hospital, New York, ³Icahn School of Medicine, New York, ⁴Sant'Orsola-Malpighi Hospital, Bologna, Italy, ⁵Complejo Hospital de Navarra, Pamplona, Spain
Background/Purpose: ANCA-associated vasculitis (AAV) is characterized by the production of auto-antibodies and can be treated with rituximab, a B cell-depleting agent. Despite this, limited data…
Abstract Number: 1955 • 2019 ACR/ARP Annual Meeting
Association of TERT and DSP Polymorphisms with Susceptibility to Myeloperoxidase-ANCA-Associated Vasculitis
Aya Kawasaki¹, Natsumi Namba ¹, Ken-ei Sada ², Fumio Hirano ³, Shigeto Kobayashi ⁴, Hidehiro Yamada ⁵, Hiroshi Furukawa ⁶, Kenji Nagasaka ⁷, Takahiko Sugihara ⁸, Aika Suzuki ⁹, Kunihiro Yamagata ¹⁰, Takayuki Sumida ¹¹, Shigeto Tohma ¹², Sakae Homma ¹³, Shoichi Ozaki ¹⁴, Hiroshi Hashimoto ¹⁵, Hirofumi Makino ¹⁶, Yoshihiro Arimura ¹⁷, Masayoshi Harigai ¹⁸ and Naoyuki Tsuchiya ¹, ¹Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ²Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Kitaku, Okayama, Japan, ³Department of Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan, ⁴Department of Internal Medicine, Juntendo University Koshigaya Hospital, Koshigaya, Japan, ⁵Center for Rheumatic diseases, Seirei Yokohama Hospital, Kawasaki, Japan, ⁶Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan, ⁷Department of Rheumatology, Ome Municipal General Hospital, Tokyo, ⁸Department of Lifetime Clinical Immunology, Tokyo Medical and Dental University, Tokyo, Japan, ⁹Department of Respiratory Medicine, Toho University Graduate School of Medicine, Tokyo, Japan, ¹⁰Department of Nephrology, University of Tsukuba, Tsukuba, Ibaraki, Japan, ¹¹Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ¹²National Hospital Organization Tokyo National Hospital, Kiyose, Japan, ¹³Department of Advanced and Integrated Interstitial Lung Diseases Research, School of Medicine, Toho University, Tokyo, Japan, ¹⁴St. Marianna University School of Medicine, Kawasaki, Japan, ¹⁵Juntendo University School of Medicine, Tokyo, Japan, ¹⁶Okayama University, Okayama, Japan, ¹⁷Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, ¹⁸Department of Rheumatology, Tokyo Women's Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan
Background/Purpose: Epidemiology of ANCA-associated vasculitis (AAV) is substantially different between East Asian and European populations. Microscopic polyangiitis (MPA) and MPO-ANCA positive AAV (MPO-AAV) are prevalent…
Abstract Number: 1661 • 2019 ACR/ARP Annual Meeting
Circulating Cell Free DNA Released from Eosinophils Is a Practical Biomarker in Patients with Eosinophilic Granulomatosis with Polyangiitis
Teppei Hashimoto¹, Yuichi Yokoyama ², Tetsuya Furukawa ³, Takahiro Yoshikawa ³, Naoto Azuma ², Kohsuke Yoshida ⁴, Akira Hashiramoto ⁴ and Kiyoshi Matsui ³, ¹Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Kobe, Hyogo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan, ³Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan, ⁴Kobe University Graduate School of Health Sciences, Kobe, Hyogo, Japan
Background/Purpose: Fragmented cell-free DNA (cfDNA) is released into blood circulation as results of damage or death of peripheral blood cells as well as organ tissues,…
Abstract Number: 2621 • 2019 ACR/ARP Annual Meeting
Association Between Outcome Renal, Clinical Variables and Findings of Renal Biopsy in Patients with ANCA Vasculitis
Linda Vergel Orduz¹, Alejandro Brigante ², Diego Marino ³, Natalia Perrotta ³, Romina Hassan ⁴, Gisele Verna ⁵, Adriana Hamaui ⁶, Eduardo Kerzberg ⁷ and Diana Dubinsky ⁶, ¹Sanatorio Guemes, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, ²Sanatorio Güemes, Servicio de Medicina Interna – Reumatología, Francisco Acuña de Figueroa 1240, C1180AAD, Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ³Hospital de Clínicas José de San Martín, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ⁴Hospital Ramos Mejía, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ⁵Sanatorio Guemes, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ⁶Sanatorio Güemes, Buenos Aires, Argentina, ⁷Hospital Ramos Mejia, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Background/Purpose: In associated ANCA vasculitis (AAV), rapidly progressive glomerulonephritis (GN) is one of the most serious complications. In 40% of cases they progress to chronic…
Abstract Number: 1662 • 2019 ACR/ARP Annual Meeting
Does PR3-ANCA+ Eosinophilic Granulomatosis with Polyangiitis (Churg–Strauss)Really Exist?
Matthias Papo¹, Renato A. Sinico ², Vítor Teixeira ³, Maria-Letizia Urban ⁴, Juliane Mahrhold ⁵, Francesco Locatelli ⁶, Giulia Cassone ⁷, Franco Schiavon ⁸, Benjamin Seeliger ⁹, Thomas Neumann ¹⁰, Claus Kroegel ¹¹, Matthieu Groh ¹², Chiara Marvisi ¹³, Maxime Samson ¹⁴, Thomas Barba ¹⁵, David Jayne ¹⁶, Bernhard Hellmich ⁵, Sara Monti ¹⁷, Carlomaurizio Montecucco ⁶, Carlo Salvarani ¹⁸, Jean-Emmanuel Kahn ¹², Cécile-Audrey Durel ¹⁵, Loic Guillevin ¹⁹, Giacomo Emmi ⁴, Augusto Vaglio ²⁰ and Benjamin Terrier ¹⁹, ¹Department of Internal Medicine, Hôpital Cochin, Université Paris Descartes, Sorbonne Paris Cité, INSERM Unité 1016, Centre de Référence pour les Maladies Auto-immunes Rares, Paris, France, Paris, France, ²Department of Medicine and Surgery, Università degli Studi di Milano - Bicocca , Italy, Milan, Italy, ³Rheumatology and Bone Diseases Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte; Lisbon, Portugal., Lisbon, Portugal, ⁴Department of Experimental and Clinical Medicine, University of Firenze, Florence, Italy, Florence, Italy, ⁵Department of Internal Medicine, Rheumatology and Immunology, Vasculitis-Center Tübingen-Kirchheim, Medius Klinik Kirchheim, University of Tübingen, Kirchheim-Teck, Germany, Kirchheim, Germany, ⁶Department of Rheumatology, IRCCS Policlinico S. Matteo Foundation, University of Pavia, Pavia, Italy, Pavia, Italy, ⁷Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy. Rheumatology Unit, IRCCS Arcispedale Santa Maria Nuova, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy, Modena and Reggio Emilia, Italy, ⁸Operative Unit of Rheumatology, Department of Medicine DIMED, University of Padova, Padova, Italy, Padova, Italy, ⁹Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany, Hannover, Germany, ¹⁰Division of Rheumatology and Immunolog, Kantonsspital St. Gallen, St. Gallen, Sankt Gallen, Switzerland, ¹¹Department of Pneumology and Allergology, Clinic of Internal Medicine I, Jena University Hospital, Jena, Germany, Jena, Germany, ¹²Service de Médecine Interne, Centre de Référence des Syndromes Hyperéosinophiliques-CEREO, Hôpital Foch, Université Versailles–Saint-Quentin-en-Yvelines, Suresnes, France, Suresnes, France, ¹³Nephrology Unit, Parma University Hospital, Parma, Italy, Parma, Italy, ¹⁴CHU Dijon, Dijon, France, ¹⁵Department of Internal Medicine, Hôpital Edouard Herriot, Lyon, France, Lyon, France, ¹⁶Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, UK, Cambridge, United Kingdom, ¹⁷University of Pavia, Pavia, Italy, ¹⁸Division of Rheumatology, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, ¹⁹National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France, ²⁰Nephrology Unit, Parma University Hospital, Parma, Italy, Nephrology Unit, Parma University Hospital, Parma, Italy, Italy
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) (Churg–Strauss) is a small-vessel necrotizing vasculitis characterized by blood and tissue eosinophilia and asthma. Only a third of EGPA…
Abstract Number: 2625 • 2019 ACR/ARP Annual Meeting
Predictors of Advanced Chronic Kidney Disease in Patients with ANCA Vasculitis and Renal Involvement
Gelsomina Alle¹, John Jaramillo Gallego ², Marina Scolnik ³, Valeria Scaglioni ², Martin Brom ⁴, Carlos Varela ⁵, Gustavo Greloni ⁵ and Enrique Soriano ⁶, ¹Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina, Ciudad Autónoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ²Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina, Ciudad Autónoma de Buenos Aires, Argentina, ³Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ⁴Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina, Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ⁵Nephrology Service, Hospital Italiano de Buenos Aires, Argentina, Ciudad Autónoma de Buenos Aires, Argentina, ⁶Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina., Buenos Aires, Buenos Aires, Argentina
Background/Purpose: The aim of this study was to evaluate the predictors of advanced chronic kidney disease (ACKD) in patients with Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis…

« Previous Page
1
…
5
6
7
8
9
…
20
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.